Our Experties..

Press View

Press View database covers global pharmaceutical and biotech companies daily announcements on drug development and corporate updates.

Database covers more than 4,500 active companies that includes development and commercial drugs companies.

  • Currently covers more than 22,000 press releases from 2016 to till date
  • Key features are Drug Name, Company Name, Event Type, Deal Value, Future Date, Future Date Event and Drug Nature
  • Graphical view by Event Type, Trial Events, Development Stage and Disease Area
  • Export data option to view and client can create customized data templates

Customized support for the below data fields,

  • Drug unique features NME, First-in-Class and Regulatory Designations
  • Latest peer reviewed journals from ASCO, NEJM, ESMO, and ASH
  • Historical Drug Sales and Patents

R&DTrend View

Provides comprehensive analysis on drug research and market innovations with key data attributes.

Drug research expenses and success rates depends on molecule type and indication,

  • New molecule or therapy innovations are highly challenging and very expensive
  • New delivery or enhancements to the new molecule innovations are less time consuming and cost effective
  • Generic or Biosimilar drug development is alternate therapy to the expensive therapy

Trend analysis covers detailed information on Companies, Drugs, Patents and Sales. Topics covered in the database are,

  • Extended Release Drugs
  • 505b2 Drugs
  • NME Drug Approvals from 2000-2019

Future topics,

  • AAV based Pipeline Drugs
  • siRNA Approved and Pipeline Drugs
  • Antibody-drug conjugates or ADCs
  • Early stage Biologic Drugs
  • PDUFA drugs

Latest News

Nanobiotix Announces Publication in Lancet Oncology of Phase III Data in Soft Tissue Sarcoma for NBTXR3 as its First Product in a New Class

The Medical Research Council funds XBiotech's Phase 2 multi-center study with bermekimab in advanced cancer patients

Latest News

Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis